Boehringer Ingelheim, AstraZeneca and Glaxo Smith Kline have announced that they will begin limiting out-of-pocket costs for inhalers for eligible patients to $35/month.
This program will start on June 1, 2024 at retail pharmacies. This price cap does not apply to government-sponsored health plans such as Medicare, Medicaid, or VA benefits.
